Boehringer Ingelheim Expands Cancer Research at Vienna Site
On Sep. 25, German biopharma company Boehringer Ingelheim opened its new 11,000 sqm Angelika Amon Research Building at its site in Vienna, Austria. According to Boehringer Ingelheim, the investment of around €60 million is further proof of the company's commitment to cancer research.
The new building, which offers space for 150 people working on therapeutic approaches against cancer, is named after the Viennese cancer researcher Angelika Amon who was closely connected to Boehringer Ingelheim, the company explained.
The completion of the new research building is just one of many investments made by the company. Last year, Boehringer announced a 5-year plan, covering €7.0 billion capital investment. In 2023, capital expenditure reached €1.2 billion under this program, the company said. Over the past five years, Boehringer’s capital investments amounted to €6.0 billion.
"Our goal is to create more health for humans and animals," commented Paola Casarosa, head of Boehringer’s innovation unit. "Especially in the field of oncology, there is still a massive unmet medical need."
Norbert Kraut, global head of cancer research at Boehringer, added: "Our declared goal is to cure cancer. The big challenge is that cancer is not a single disease, but a term for different diseases of different organs. In the future, around one third of the new products at Boehringer Ingelheim will come from oncology."
